JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$5.47B |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$3.17B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$2.05B |
| 4 |
Amazon
AMZN
|
+$1.96B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$1.72B |
| 2 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
+$1.31B |
| 3 |
UnitedHealth
UNH
|
+$1.26B |
| 4 |
Automatic Data Processing
ADP
|
+$1.17B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.08B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.28% |
| 2 | Technology | 17.17% |
| 3 | Healthcare | 10.79% |
| 4 | Financials | 9.36% |
| 5 | Consumer Discretionary | 8.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
MPX
5251
DELISTED
Marine Products Corp
MPX
| $85K | ﹤0.01% |
6,411
+1,663
| +35% | +$21.7K |
2017 Q4
21 quarters
|
|
|
MYD
5252
DELISTED
BlackRock MuniYield Fund
MYD
| $84.3K | ﹤0.01% |
+7,843
| New | +$84.2K |
2023 Q1
0 quarters
|
|
5253
Acrivon Therapeutics
ACRV
$84.8M
| $84K | ﹤0.01% |
+6,630
| New | +$111K |
2023 Q1
0 quarters
|
|
5254
AN2 Therapeutics
ANTX
$212M
| $84K | ﹤0.01% |
8,511
+2,247
| +36% | +$25K |
2022 Q2
3 quarters
|
|
5255
Caesarstone
CSTE
$101M
| $84K | ﹤0.01% |
20,479
-654
| -3% | -$3.63K |
2013 Q2
39 quarters
|
|
5256
Direxion Daily MSCI Emerging Markets Bear 3X ETF
EDZ
$26.4M
| $84K | ﹤0.01% |
+675
| New | +$83.1K |
2023 Q1
0 quarters
|
|
5257
Eaton Vance Tax-Advantaged Dividend Income Fund
EVT
$2.07B
| $84K | ﹤0.01% |
+3,714
| New | +$86.5K |
2023 Q1
0 quarters
|
|
5258
First Trust Smith Opportunistic Fixed Income ETF
FIXD
$2.86B
| $84K | ﹤0.01% |
1,847
+1,347
| +269% | +$60.4K |
2021 Q1
8 quarters
|
|
5259
NI Holdings
NODK
$305M
| $84K | ﹤0.01% |
6,480
+690
| +12% | +$9.24K |
2017 Q4
21 quarters
|
|
5260
Oportun Financial
OPRT
$385M
| $84K | ﹤0.01% |
21,798
+5,814
| +36% | +$32.7K |
2019 Q3
14 quarters
|
|
|
PARAA
5261
DELISTED
Paramount Global Class A
PARAA
| $84K | ﹤0.01% |
3,259
+147
| +5% | +$3.64K |
2019 Q4
13 quarters
|
|
|
CTV
5262
DELISTED
Innovid Corp.
CTV
| $84K | ﹤0.01% |
59,291
+15,679
| +36% | +$28.6K |
2022 Q1
4 quarters
|
|
5263
Alto Ingredients
ALTO
$294M
| $83K | ﹤0.01% |
55,339
+14,052
| +34% | +$38.5K |
2021 Q1
8 quarters
|
|
5264
GeneDx Holdings
WGS
$2.27B
| $83K | ﹤0.01% |
6,902
+3,520
| +104% | +$46.9K |
2021 Q4
5 quarters
|
|
5265
TELA Bio
TELA
$51.5M
| $82K | ﹤0.01% |
7,712
-2,922
| -27% | -$32.2K |
2022 Q3
2 quarters
|
|
5266
USCB Financial Holdings
USCB
$415M
| $82K | ﹤0.01% |
8,258
+2,156
| +35% | +$25.9K |
2021 Q4
5 quarters
|
|
|
FM
5267
DELISTED
iShares Frontier and Select EM ETF
FM
| $82K | ﹤0.01% |
+3,196
| New | +$81.9K |
2023 Q1
0 quarters
|
|
5268
DNP Select Income Fund
DNP
$3.59B
| $81.9K | ﹤0.01% |
7,430
-1,929
| -21% | -$21.9K |
2022 Q4
1 quarter
|
|
5269
ALX Oncology
ALXO
$167M
| $81K | ﹤0.01% |
17,807
+4,391
| +33% | +$33.3K |
2020 Q3
10 quarters
|
|
5270
Leonardo DRS
DRS
$9.77B
| $81K | ﹤0.01% |
6,253
-15,449
| -71% | -$200K |
2022 Q4
1 quarter
|
|
|
EXAS
5271
PUT
DELISTED
Exact Sciences
EXAS
| $81K | ﹤0.01% |
1,200
-25,800
| -96% | -$1.66M |
2022 Q1
4 quarters
|
|
5272
Nuveen ESG Emerging Markets Equity ETF
NUEM
$498M
| $80.8K | ﹤0.01% |
3,009
+3
| +0.1% | +$81 |
2022 Q4
1 quarter
|
|
5273
State Street SPDR Dow Jones International Real Estate ETF
RWX
$239M
| $80K | ﹤0.01% |
3,048
+17
| +0.6% | +$464 |
2014 Q4
33 quarters
|
|
5274
Xtrackers USD High Yield Corporate Bond ETF
HYLB
$3.2B
| $80K | ﹤0.01% |
2,307
-27
| -1% | -$927 |
2018 Q3
18 quarters
|
|
|
WHWK
5275
Whitehawk Therapeutics
WHWK
$211M
| $80K | ﹤0.01% |
11,128
+2,896
| +35% | +$30.9K |
2022 Q2
3 quarters
|
|
Similar funds
JP Morgan Chase's Q1 2023 Portfolio in Review
As of Q1 2023, JP Morgan Chase held 7,579 positions worth $821B, up 8.2% from $759B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
JP Morgan Chase's Q1 2023 filing shows 751 new, 3,314 increased, 2,056 reduced and 652 closed positions. Its largest new stake was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M. The largest sale was Eli Lilly, an estimated $1.72B.
By sector, the portfolio is most concentrated in Miscellaneous at 27% of assets, up from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q1 2023 buy was Near Intelligence, Inc. Common Stock: 5,852,099 shares worth $14.7M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q1 2023, an estimated $5.47B increase.
- JP Morgan Chase's biggest Q1 2023 reduction was Eli Lilly, cutting an estimated $1.72B.
- JP Morgan Chase fully exited IAA, Inc. Common Stock in Q1 2023, selling an estimated $155M.
- JP Morgan Chase's ten largest holdings make up 17% of its $821B portfolio in Q1 2023.
- JP Morgan Chase opened 751 new positions and closed 652 in Q1 2023.
- JP Morgan Chase's portfolio value rose 8.2% quarter-over-quarter to $821B.
Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.